$NTRA earnings report

Natera Reports Third Quarter 2026 Financial Results. AlphAI read Natera's third quarter of 2026 filing as solid. 2 quarters are on record below.

third quarter of 2026

AlphAI · Earnings readNTRA · third quarter of 2026 · ended September 30, 2026

Natera Reports Third Quarter 2026 Financial Results

✓Solid quarter

Third-quarter revenue increased 34.1%, test volume increased 22.3%, oncology test volume increased 60.9%, and the company raised its 2026 annual revenue guidance. Gross margin was slightly below the prior-year level and Natera continued to report an operating loss and net loss.

Revenue
$794M
34.1% y/y
Product revenues, three months ended September 30, 2026
$790M
Gross margin · GAAP
64.7%
EPS · GAAP
($0.42)
2026 outlook
$3.005 billion to $3.035 billion
GM approximately 64% to 66%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$794M–34.1%
Product revenues, three months ended September 30, 2026GAAP$790.0M––
Licensing and other revenues, three months ended September 30, 2026GAAP$4M––
Gross profit, three months ended September 30, 2026GAAP$513.5M––
Gross margin, three months ended September 30, 2026GAAP64.7%––
Non-GAAP gross margin, three months ended September 30, 2026, excluding changes in estimates in revenue accrualsnon-GAAPincreased by approximately 1.4% sequentiallyincreased by approximately 1.4% sequentially–
Change in estimates in revenue accruals, three months ended September 30, 2026GAAPapproximately $32.3 million––
Gross-margin increase from changes in estimates, three months ended September 30, 2026GAAP1.5%––
Tests processed, third quarter of 2026otherapproximately 1,093,100 tests–22.3%
Tests accessioned, third quarter of 2026otherapproximately 1,080,300 tests––
Tests reported, third quarter of 2026otherapproximately 1,024,800 tests–23.0%
Tests reported in laboratory, third quarter of 2026otherapproximately 1,012,100 tests––
Oncology tests processed, third quarter of 2026otherapproximately 339,500 oncology tests–60.9%
Clinical MRD oncology units, third quarter of 2026othergrew 32,700 unitsgrew 32,700 units–
Cost of product revenues, three months ended September 30, 2026GAAP$279.6M––
Cost of licensing and other revenues, three months ended September 30, 2026GAAP$871K––
Research and development expenses, three months ended September 30, 2026GAAP$242.4M––
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$333.7M––
Total operating expenses, third quarter of 2026GAAP$576.1M–19.5%
Amortization of acquired intangible assets, third quarter of 2026GAAP$5.7M––
Total cost and expenses, three months ended September 30, 2026GAAP$862.3M––
Loss from operations, third quarter of 2026GAAP$68.3M––
Interest expense, three months ended September 30, 2026GAAP$903K––
Interest and other income, net, three months ended September 30, 2026GAAP$9.61M––
Loss before income taxes, three months ended September 30, 2026GAAP$59.61M––
Income tax expense, three months ended September 30, 2026GAAP$299K––
Net loss, third quarter of 2026GAAP$59.9M––
Net loss per share, basic and diluted, third quarter of 2026GAAP($0.42) per diluted share––
Weighted-average shares used in computing basic and diluted net loss per share, third quarter of 2026GAAP144.1M––
Total revenues, nine months ended September 30, 2026GAAP$2.24B––
Product revenues, nine months ended September 30, 2026GAAP$2.23B––
Licensing and other revenues, nine months ended September 30, 2026GAAP$11.60M––
Cost of product revenues, nine months ended September 30, 2026GAAP$791.4M––
Cost of licensing and other revenues, nine months ended September 30, 2026GAAP$2.44M––
Research and development expenses, nine months ended September 30, 2026GAAP$681.2M––
Selling, general and administrative expenses, nine months ended September 30, 2026GAAP$988.8M––
Amortization of acquired intangible assets, nine months ended September 30, 2026GAAP$17.12M––
Total cost and expenses, nine months ended September 30, 2026GAAP$2.48B––
Loss from operations, nine months ended September 30, 2026GAAP$237.6M––
Net loss, nine months ended September 30, 2026GAAP$212.0M––
Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP$(1.48)––
Cash, cash equivalents and restricted cash, September 30, 2026GAAP$1.10Bincreased by approximately $5.7 million–
Total outstanding debt balance, September 30, 2026GAAP$80.3M––

Segments

SegmentRevenueq/qy/y
Product revenues, three months ended September 30, 2026The release cited an increase in volume and average selling price improvements for the increase in revenues.$790.0M––
Licensing and other revenues, three months ended September 30, 2026No separate driver was provided.$4M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

2026 outlook

  • Revenue$3.005 billion to $3.035 billion
  • Gross marginapproximately 64% to 66%
  • NoteSelling, general and administrative costs: approximately $1.225 billion to $1.300 billion
  • NoteResearch and development costs: $825 million to $925 million
  • NoteCash flow to be positive

What drove it

  • Revenue growth was driven by an increase in volume and average selling price improvements.
  • Oncology test volume increased 60.9% to approximately 339,500 oncology tests.
  • Clinical MRD oncology units grew 32,700 units over the second quarter of 2026.
  • The increase in operating expenses was primarily driven by headcount growth to support new product offerings and increases in clinical trial expenses.
  • Gross profit reflected higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates.

Concerns

  • GAAP gross margin was 64.7%, compared to 64.9% in the third quarter of 2025.
  • Natera reported a loss from operations of $68.3 million and a net loss of $59.9 million in the third quarter of 2026.
  • The benefit to gross margin from changes in estimates was 1.5%, compared to 3.6% in the third quarter of 2025.
  • Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.

What to watch

  • Execution against 2026 total revenue guidance of $3.005 billion to $3.035 billion.
  • Whether gross margin remains within the approximately 64% to 66% 2026 outlook range.
  • Progress toward the outlook for positive cash flow.
  • Oncology test volume and clinical MRD oncology unit growth.
  • Selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.

Balance sheet and cash flow

  • Cash, cash equivalents and restricted cash were $1,097.2 million at September 30, 2026, compared to $1,076.1 million as of December 31, 2025.
  • Cash increased by approximately $5.7 million as of September 30, 2026 compared to June 30, 2026.
  • Total outstanding debt balance was $80.3 million as of September 30, 2026, including accrued interest under the line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
  • Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.
  • Inventory was $91,704 (in thousands) at September 30, 2026, compared to $68,443 (in thousands) at December 31, 2025.

Analysis

Natera delivered $794.0 million of third-quarter revenue, up 34.1% from $592.2 million in the third quarter of 2025. The release attributed the increase to higher volume and average selling price improvements. Tests processed increased 22.3% to approximately 1,093,100, while tests reported increased 23.0% to approximately 1,024,800. Oncology tests processed increased 60.9% to approximately 339,500, and clinical MRD oncology units grew 32,700 units over the second quarter of 2026.

Profitability improved in dollar terms but remained negative. Gross profit was $513.5 million, while GAAP gross margin was 64.7%, compared with 64.9% in the prior-year quarter. The company said gross profit benefited from higher revenue and cost-of-revenue reduction efforts, offset by a smaller benefit from changes in estimates. Changes in estimates increased gross margin by 1.5% in the quarter, versus 3.6% in the comparable 2025 period. Excluding revenue-accrual estimate changes, non-GAAP gross margin increased by approximately 1.4% sequentially.

Operating expenses were $576.1 million, up 19.5% from $482.0 million, primarily due to headcount supporting new product offerings and higher clinical trial expenses. Research and development expenses were $242,433 (in thousands), selling, general and administrative expenses were $333,656 (in thousands), and acquired-intangible amortization was $5.7 million. Loss from operations narrowed to $68.3 million from $97.6 million, while net loss narrowed to $59.9 million, or ($0.42) per diluted share, from $87.5 million, or ($0.64) per diluted share.

Liquidity was $1,097.2 million of cash, cash equivalents and restricted cash at September 30, 2026, an increase of approximately $5.7 million from June 30, 2026. Total outstanding debt was $80.3 million. Natera raised annual revenue guidance by $140 million at the midpoint to $3.005 billion to $3.035 billion and retained a gross-margin outlook of approximately 64% to 66%. The company also expects cash flow to be positive, with selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.

Not in the filing

stated, not guessed
  • Prior-release outlook for formal actual-versus-prior-guidance comparison
  • Operating cash flow for the reported quarter and nine-month period
  • Free cash flow for the reported quarter and nine-month period
  • Share repurchases
  • Dividend declaration or payment
  • Non-GAAP net income or loss
  • Non-GAAP EPS
  • Operating segment revenue disclosure
  • Tax-rate guidance
  • Quarterly GAAP total revenue prior-quarter comparison
  • Quarterly GAAP gross-margin percentage change versus the prior year
  • Named executive quotations

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readNTRA · second quarter of 2026 · ended June 30, 2026

Natera Reports Second Quarter 2026 Financial Results

✓Strong quarter

Total revenues increased 37.7%, test volumes increased 22.4%, gross margin expanded to 64.5%, and net loss narrowed to $67.0 million. The company also raised 2026 annual revenue guidance by $100 million at the midpoint.

Revenue
$753M
37.7% y/y
Gross margin · GAAP
64.5%
EPS · GAAP
($0.47)
2026 outlook
$2.85 billion to $2.91 billion
GM approximately 64% to 66%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$752.8M–37.7%
Gross profitGAAP$485.2M––
Gross marginGAAP64.5%––
Non-GAAP gross-margin sequential improvement, excluding revenue true-upsnon-GAAPapproximately 0.5%approximately 0.5%–
Total operating expensesGAAP$555.3M–21.5%
Amortization of acquired intangible assetsGAAP$5.7M––
Loss from operationsGAAP$75.8M––
Net lossGAAP$67M––
Net loss per diluted shareGAAP($0.47) per diluted share––
Weighted average shares outstandingGAAP143.3M––
Tests processedotherapproximately 1,043,900 tests–22.4%
Tests accessioned in laboratoryotherapproximately 1,030,100 tests––
Tests reportedotherapproximately 985,500 tests–21.2%
Tests reported in laboratoryotherapproximately 972,000 tests––
Oncology tests processedotherapproximately 296,700 oncology tests–57.2%
Clinical molecular residual disease oncology-unit growthother34,000 units34,000 units–
Change in estimate in revenue accrualGAAPapproximately $52.3 million––
Gross-margin impact from changes in estimatesGAAP2.7%––
Gross-profit impact from changes in estimatesGAAP$52.3M––

2026 outlook

  • Revenue$2.85 billion to $2.91 billion
  • Gross marginapproximately 64% to 66%
  • NoteSelling, general and administrative costs to be approximately $1.125 billion to $1.225 billion
  • NoteResearch and development costs to be $800 million to $900 million
  • NoteCash flow to be positive

What drove it

  • Revenue growth was driven by an increase in volume and average selling price improvements.
  • Higher gross margin was primarily the result of higher revenues and continued progress in reducing cost of revenues associated with tests processed.
  • Operating-expense growth was primarily driven by headcount growth to support new product offerings and increases in clinical trial expenses.
  • Oncology test volume increased 57.2%, and clinical molecular residual disease oncology units recorded the largest sequential increase to-date.
  • Signatera achieved three significant regulatory approvals, Medicare coverage expanded for Prospera, and Natera launched a major enhancement to Panorama NIPT.

Concerns

  • Natera reported a net loss of $67.0 million and loss from operations of $75.8 million.
  • Total operating expenses increased 21.5% to $555.3 million, reflecting headcount growth and clinical trial expenses.
  • Changes in estimates for revenue accrual increased revenue, gross margin, and gross profit by 2.7% and $52.3 million, respectively.
  • The company had a total outstanding debt balance of $80.3 million including accrued interest under its UBS line of credit.

What to watch

  • Delivery against 2026 total revenue guidance of $2.85 billion to $2.91 billion.
  • Sustainability of gross margin within guidance of approximately 64% to 66%, including progress in reducing cost of revenues associated with tests processed.
  • Oncology-volume growth and further clinical molecular residual disease oncology-unit additions.
  • Selling, general and administrative costs of approximately $1.125 billion to $1.225 billion and research and development costs of $800 million to $900 million.
  • Whether cash flow becomes positive, as anticipated in the 2026 outlook.

Balance sheet and cash flow

  • Increased cash by approximately $3.6 million during the second quarter of 2026.
  • At June 30, 2026, Natera held approximately $1,091.5 million in cash, cash equivalents, and restricted cash, compared to $1,076.1 million as of December 31, 2025.
  • As of June 30, 2026, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.

Analysis

Natera reported strong second-quarter growth, with total revenues of $752.8 million, up 37.7% from $546.6 million. The release attributed the revenue increase to higher volume and average selling price improvements. Test throughput supported that growth: tests processed increased 22.4% to approximately 1,043,900 tests, while tests reported increased 21.2% to approximately 985,500 tests. Oncology was the principal volume-growth highlight, with approximately 296,700 oncology tests processed, up 57.2%.

Gross profit rose to $485.2 million and gross margin increased to 64.5% from 63.4%. Management cited higher revenue and progress reducing test-processing costs as the primary factors. Reported gross margin was below the 64.7% reported for the three months ended March 31, 2026, while the company said non-GAAP gross margin, excluding changes in revenue-accrual estimates, increased by approximately 0.5% sequentially. The estimate change increased second-quarter revenue, gross margin, and gross profit by 2.7% and $52.3 million, respectively, making the underlying-margin progression an important point of focus.

Operating expenses increased 21.5% to $555.3 million, driven by headcount growth for new product offerings and higher clinical trial expenses. Despite that spending growth, loss from operations narrowed to $75.8 million from $110.4 million and net loss narrowed to $67.0 million from $100.9 million. Diluted net loss per share improved to ($0.47) from ($0.74), although weighted average shares outstanding increased to 143.3 million from 136.4 million.

Liquidity increased during the quarter, with cash, cash equivalents, and restricted cash of approximately $1,091.5 million at June 30, 2026, compared with $1,076.1 million at December 31, 2025. Natera also reported $80.3 million of total outstanding debt including accrued interest under its UBS line of credit. The company did not report dividends or share repurchases in the filing.

Management raised 2026 annual revenue guidance by $100 million at the midpoint and now anticipates $2.85 billion to $2.91 billion of total revenue. It guided to approximately 64% to 66% gross margin, selling, general and administrative costs of approximately $1.125 billion to $1.225 billion, research and development costs of $800 million to $900 million, and positive cash flow. The outlook places execution emphasis on sustaining oncology growth, maintaining margin performance after excluding revenue true-ups, and converting revenue growth into positive cash flow while funding commercial and clinical expansion.

Management, verbatim

We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology volumes. We also reached several landmark milestones in the last few months: Signatera™ achieved three significant regulatory approvals, Medicare coverage expanded for Prospera™, and we launched a major enhancement to our Panorama™ NIPT.

Steve Chapman, chief executive officer of Natera

Not in the filing

stated, not guessed
  • Segment revenue and segment profitability were not disclosed.
  • GAAP operating cash flow was not disclosed.
  • Free cash flow was not disclosed.
  • Dividends and share repurchases were not disclosed.
  • Non-GAAP net income and non-GAAP EPS were not disclosed.
  • A tax-rate metric and tax-rate guidance were not disclosed.
  • Separate second-quarter research and development expense and selling, general and administrative expense amounts were not disclosed.
  • Prior-quarter total revenue, operating expenses, operating loss, net loss, EPS, and test-volume metrics were not disclosed.
  • Previous-release outlook was not provided; therefore, no actual-versus-prior-guidance comparisons are included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about NTRA earnings dates

When is Natera's next earnings date?
AlphAI has no date for NTRA yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.